Testing effectiveness (Phase 2)Active Not RecruitingNCT05262023
What this trial is testing
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
Who this might be right for
Frontotemporal Dementia
Denali Therapeutics Inc. 85